245 related articles for article (PubMed ID: 38491523)
1. Machine learning-driven prognostic analysis of cuproptosis and disulfidptosis-related lncRNAs in clear cell renal cell carcinoma: a step towards precision oncology.
Chen R; Wu J; Che Y; Jiao Y; Sun H; Zhao Y; Chen P; Meng L; Zhao T
Eur J Med Res; 2024 Mar; 29(1):176. PubMed ID: 38491523
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
5. Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma.
Sun Z; Wang J; Fan Z; Yang Y; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Jiang T; Liu Y; Yang Q; Ma B
J Gene Med; 2024 Jan; 26(1):e3608. PubMed ID: 37897262
[TBL] [Abstract][Full Text] [Related]
6. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
[TBL] [Abstract][Full Text] [Related]
7. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
8. Disulfideptosis-associated lncRNAs reveal features of prognostic, immune escape, tumor mutation, and tumor malignant progression in renal clear cell carcinoma.
Li X; Deng X; Liu T; Zhang W; Tao J
Aging (Albany NY); 2024 Feb; 16(4):3280-3301. PubMed ID: 38334964
[TBL] [Abstract][Full Text] [Related]
9. Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer.
Xu L; Wang S; Zhang D; Wu Y; Shan J; Zhu H; Wang C; Wang Q
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16511-16523. PubMed ID: 37712959
[TBL] [Abstract][Full Text] [Related]
10. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics analysis and experimental validation of cuproptosis-related lncRNA LINC02154 in clear cell renal cell carcinoma.
Shen J; Wang L; Bi J
BMC Cancer; 2023 Feb; 23(1):160. PubMed ID: 36797708
[TBL] [Abstract][Full Text] [Related]
12. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C
Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910
[TBL] [Abstract][Full Text] [Related]
13. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B
Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235
[TBL] [Abstract][Full Text] [Related]
15. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H
Front Genet; 2022; 13():938259. PubMed ID: 35910212
[No Abstract] [Full Text] [Related]
16. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
17. Unveiling the hidden role of disulfidptosis in kidney renal clear cell carcinoma: a prognostic signature for personalized treatment.
Ye Y; Zeng S; Hu X
Apoptosis; 2024 Jun; 29(5-6):693-708. PubMed ID: 38296888
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data.
Zeng JH; Lu W; Liang L; Chen G; Lan HH; Liang XY; Zhu X
J Transl Med; 2019 Aug; 17(1):281. PubMed ID: 31443717
[TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs.
Wei M; Lu L; Luo Z; Ma J; Wang J
BMC Gastroenterol; 2024 Apr; 24(1):142. PubMed ID: 38654165
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]